Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

INTRODUCTION: To evaluate the efficacy and safety of secukinumab 150 mg, with or without a loading regimen, using a self-administered prefilled syringe in patients with ankylosing spondylitis (AS) over 104 weeks from the MEASURE 4 study. METHODS: Patients (N = 350) with active AS were randomized (1:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivitz, Alan J., Wagner, Ulf, Dokoupilova, Eva, Supronik, Jerzy, Martin, Ruvie, Talloczy, Zsolt, Richards, Hanno B., Porter, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251842/
https://www.ncbi.nlm.nih.gov/pubmed/30121827
http://dx.doi.org/10.1007/s40744-018-0123-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251842/
https://www.ncbi.nlm.nih.gov/pubmed/30121827
http://dx.doi.org/10.1007/s40744-018-0123-5

Ejemplares similares